Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6406-6412

  Svensson, Elin M ^a   Dooley, Kelly E ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG COMBINATION; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; QUINOLINE DERIVATIVE; RITONAVIR; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; SIMULATION; TUBERCULOSIS; BLOOD; CLINICAL TRIAL; COINFECTION; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COINFECTION; DIARYLQUINOLINES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NEVIRAPINE; RITONAVIR; TUBERCULOSIS; YOUNG ADULT;

EID: 84908191526     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03246-14     Document Type: Article

References (39)

1. World Health Organization. 2013. Global tuberculosis report. World Health Organization, Geneva, Switzerland.
2. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. 2010. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 362:697-706. http://dx.doi.org/10.1056/NEJMoa0905848.
3. Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy J-F, Goldfeld AE. 2011. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365:1471-1481. http://dx.doi.org/10.1056/NEJMoa1013911.
4. World Health Organization. 2014.WHOpolicy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. World Health Organization, Geneva, Switzerland.
5. World Health Organization. 2014. Anti-tuberculosis drug resistance in the world: fourth global report. World Health Organization, Geneva, Switzerland.
6. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. http://dx.doi.org/10.1016/S0140-6736(06)69573-1.
7. Dooley KE, Kim PS, Williams SD, Hafner R. 2012. TB and HIV therapeutics: pharmacology research priorities. AIDS Res. Treat. 2012:874083. http://dx.doi.org/10.1155/2012/874083.
8. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
9. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3:323-324. http://dx.doi.org/10.1038/nchembio884.
10. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. 2012. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56:3271-3276. http://dx.doi.org/10.1128/AAC.06126-11.
11. FDA Office of Antimicrobial Products. 2014. Briefing package, NDA 204-384, Sirturo (bedaquiline 100 mg tablets), for the treatment of adults (≥18 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB). Food and Drug Administration, Silver Spring, MD.
12. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group. 2014. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med. 371:723-732. http://dx.doi.org/10.1056/NEJMoa1313865.
13. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. 2013. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 57:2199-2203. http://dx.doi.org/10.1128/AAC.02243-12.
14. Janssen Pharmaceuticals. 2014. Sirturo, United States product insert. Janssen Pharmaceuticals, Beerse, Belgium. http://www.sirturo.com/sites/default/files/pdf/sirturo-pi.pdf.
15. Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, Zhan S. 26 November 2013. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am. J. Ther. http://dx.doi.org/10.1097/01.mjt.0000433951.09030.5a.
16. van Heeswijk RPG, Dannemann B, Hoetelmans RMW. 23 May 2014. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J. Antimicrob. Chemother. http://dx.doi.org/10.1093/jac/dku171.
17. Janssen Pharmaceuticals. 2014. Anti-Infective Drugs Advisory Committee meeting briefing document: TMC207 (bedaquiline): treatment of patients with MDR-TB. Janssen Pharmaceuticals, Beerse, Belgium. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm329260.pdf.
18. Svensson EM, Aweeka F, Park J-G, Marzan F, Dooley KE, Karlsson MO. 2013. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob. Agents Chemother. 57:2780-2787. http://dx.doi.org/10.1128/AAC.00191-13.
19. Lamson M, MacGregor T, Riska P, Erickson D, Maxfield P, Rowland L, Gigliotti M, Robinson P, Azzam S, Keirns J. 1999. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clin. Pharmacol. Ther. 65:137-137.
20. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277: 423-431.
21. Eagling VA, Back DJ, Barry MG. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:190-194.
22. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan L-S. 2002. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30:795-804. http://dx.doi.org/10.1124/dmd.30.7.795.
23. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR. 1998. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. 46:111-116.
24. McLeay SC, Vis P, van Heeswijk RPG, Green B. 23 June 2014. The population pharmacokinetics of bedaquiline (TMC207), a novel anti-tuberculosis drug. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.01418-13.
25. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13: 143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
26. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. 2012. NONMEM user's guides (1989 -2012). Icon Development Solutions, Ellicott City, MD.
27. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. 2005. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257. http://dx.doi.org/10.1016/j.cmpb.2005.04.005.
28. Jonsson EN, Karlsson MO. 1999. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
29. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. 2011. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput. Methods Programs Biomed. 101:72-79. http://dx.doi.org/10.1016/j.cmpb.2010.04.018.
30. de Maat DMMR, Ekhart GC, Huitema ADR, Koks CHW, Mulder JW, Beijnen JH. 2003. Drug interactions between antiretroviral drugs and comedicated agents. Clin. Pharmacokinet. 42:223-282. http://dx.doi.org/10.2165/00003088-200342030-00002.
31. Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF, AIDS Clinical Trials Group Protocol (ACTG 378) Study Team. 2003. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin. Pharmacol. Ther. 73:406-416. http://dx.doi.org/10.1016/S0009-9236(03)00006-7.
32. Mesens N, Steemans M, Hansen E, Verheyen GR, Van Goethem F, Van Gompel J. 2010. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol. In Vitro 24:1417-1425. http://dx.doi.org/10.1016/j.tiv.2010.04.007.
33. Reasor MJ, Hastings KL, Ulrich RG. 2006. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 5:567-583. http://dx.doi.org/10.1517/14740338.5.4.567.
34. Food and Drug Administration. 2014. The regulatory challenges of drug-induced phospholipidosis. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/advisorycommitteeforpharmaceuticalscienceandclinicalpharmacology/ucm210798.pdf.
35. Peresi E, Silva SMUR, Calvi SA, Marcondes-Machado J. 2008. Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. J. Bras. Pneumol. 34: 942-949. http://dx.doi.org/10.1590/S1806-37132008001100009.
36. Ramakrishnan K, Shenbagarathai R, Kavitha K, Uma A, Balasubramaniam R, Thirumalaikolundusubramanian P. 2008. Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV. Jpn. J. Infect. Dis. 61:202-204.
37. Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA. 2002. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis 82:91-96. http://dx.doi.org/10.1054/tube.2002.0330.
38. Van Heeswijk R, Lachaert R, Leopold L, DeBeule K, McNeeley D, Hoetelmans R. 2007. The effect of CYP3A4 inhibition on the clinical pharmacokinetics of TMC207. abstr PS-71358-11. Proc. 38th World Conf. Lung Health, Cape Town, South Africa.
39. Mesens N, Verbeeck J, Rouan M. 2007. Elucidating the role of M2 in the preclinical safety profile of TMC207, abstr PS-71291-11. Proc. 38th World Conf. Lung Health, Cape Town, South Africa.